What kind of company is Hwa Guang?

Hwa Guang is a biotech and pharmaceutical company focused on R&D, manufacturing, and sales, especially in diabetes and endocrinology.

Why lift the director's non-compete restriction?

To enable top executives to contribute across organizations, ensuring governance flexibility without conflicts of interest.

Is this resolution important for investors?

Yes. It signals transparent governance and operational flexibility, impacting long-term corporate value.

Hwa Guang Announces Shareholders' Approval to Lift Non-Competition Restriction for Director Fan Pu

Published Jun 26, 2026 9:00 AM ・ Updated Jun 27, 2026 6:34 PM ・ 9 min read ・ Source: PR Times

On June 26, 2026, Hwa Guang's annual shareholders' meeting approved the lifting of non-competition restrictions for Director Fan Pu, allowing him to engage in biotech and pharmaceutical advisory roles at other firms, provided no harm to Hwa Guang's interests. The resolution passed with 98.02% support.

1. Shareholders' Meeting Resolution Date: 115/06/26

2. Name and Title of Director Permitted to Engage in Competitive Activities: Director: Fan Pu, Representative of Tonghua Dongbao Pharmaceutical Co., Ltd.

3. Permitted Competitive Activities: Lifting the restriction under Article 209 of the Company Act for Director Fan Pu to engage in biotechnology, bio-techniques, biopharmaceuticals, and biotech industry advisory services at other companies, provided that Hwa Guang’s interests are not compromised.

4. Duration of Permission for Competitive Activities: During the period of serving as a director of Hwa Guang.

5. Voting Results (as required by Article 209 of the Company Act): Total voting rights present during voting: 53,304,833 Votes in favor: 52,249,757 (98.02%) Votes against: 59,213 (0.11%) Invalid votes: 0 (0%) Abstentions / Non-votes: 995,863 (1.86%) Resolution Outcome: The proposal was approved as submitted following shareholder voting.

6. Director’s Name and Title if the Permitted Competitive Activity Involves Businesses in Mainland China (Enter 'Not Applicable' if not applicable): Fan Pu, Representative of Tonghua Dongbao Pharmaceutical Co., Ltd.

7. Director’s Positions in the Mainland China-Based Enterprises: Director Fan Pu, appointed as legal representative by Tonghua Dongbao Pharmaceutical Co., Ltd., holds the following positions: - Vice President, Tonghua Dongbao Pharmaceutical Co., Ltd. - General Manager and Executive Director, Tianjin Runxin Enterprise Management Co., Ltd. - Authorized Representative of Managing Partner, Tianjin Runhe Enterprise Management Partnership - Chairman, Benyuan Zhengyang Gene Technology Co., Ltd. - Director, Dongbao International (Hong Kong) Limited

8. Addresses of the Mainland China-Based Enterprises: (1) Tonghua Dongbao Pharmaceutical Co., Ltd.: Dongbao Xincun, Tonghua County, Jilin Province (2) Tianjin Runxin Enterprise Management Co., Ltd.: Room 201, Building K10, International Enterprise Community, Changyuan Road, Wuqing Development Zone, Tianjin (3) Tianjin Runhe Enterprise Management Partnership: Room 201, Building K10, International Enterprise Community, Changyuan Road, Wuqing Development Zone, Tianjin (4) Benyuan Zhengyang Gene Technology Co., Ltd.: No. 6 Yongchang Zhong Road, Beijing Economic-Technological Development Area, Beijing (5) Dongbao International (Hong Kong) Limited: UNIT 1021 BEVERLEY COMMERCIAL CENTRE 87-105 CHATHAM ROAD SOUTH TSIM SHA TSUI HK

9. Business Scope of the Mainland China-Based Enterprises: (1) Tonghua Dongbao Pharmaceutical Co., Ltd.: Hard capsules, tablets (including hormone-containing), granules, small-volume injectables, active pharmaceutical ingredients (recombinant human insulin), biotech products (recombinant human insulin injection), surgical, emergency, and diagnostic equipment and instruments, injection and puncture devices, clinical analysis instruments and diagnostic reagents (including diagnostic reagents), medical laboratory and basic equipment. Primarily engaged in R&D, manufacturing, and sales of biopharmaceuticals, traditional Chinese medicine, and chemical drugs in the fields of diabetes and endocrinology. (2) Tianjin Runxin Enterprise Management Co., Ltd.: Enterprise management and consulting. (3) Tianjin Runhe Enterprise Management Partnership: Enterprise management, marketing planning, and information consulting. (4) Benyuan Zhengyang Gene Technology Co., Ltd.: Research and development of new gene diagnosis and therapy technologies, production and sales of related products permitted by policy, and investment in biotech high-tech fields. (5) Dongbao International (Hong Kong) Limited: Pharmaceutical import/export, import/export agency, supply chain management services, and information economic consulting services.

10. Impact on Hwa Guang’s Financial and Operational Performance: None

11. If the Director has invested in the Mainland China-based enterprises, the investment amount and shareholding ratio: Director Fan Pu, representative of Tonghua Dongbao Pharmaceutical Co., Ltd., has invested in the following Mainland China entities: (1) Tianjin Runxin Enterprise Management Co., Ltd.: Investment of RMB 5,000, shareholding ratio 16.6667% (2) Tianjin Runhe Enterprise Management Partnership: Investment of RMB 1,705,100, shareholding ratio 4.7736%

12. Other Matters to be Disclosed: None

FACT BOX

Source: PR Times
Category: News
Dates in source: 115/06/26

Hwa Guang Announces Shareholders' Approval to Lift Non-Competition Restriction for Director Fan Pu

⚡ Key Points

FACT BOX

Editorial & Verification Standards

FAQ

Cite this article — HOW TO CITE

AI CRAWLER ACTIVITY